RecruitingPhase 2NCT06510426

Early Interferon-beta Treatment for West-Nile Virus Infection


Sponsor

Tel-Aviv Sourasky Medical Center

Enrollment

100 participants

Start Date

Jul 14, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease. The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rebif 44 MCG Per 0.5 ML Prefilled Syringe and a drug called Saline for people with west nile fever encephalitis, west nile fever myelitis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRebif 44 MCG Per 0.5 ML Prefilled Syringe

Rebif 44mcg per 0.5ml administered subcutaneously

DRUGSaline

0.5mL of saline administered subcutaneously


Locations(1)

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06510426


Related Trials